Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark. Show more

Location: Ole Maaloes Vej 3, Copenhagen, 2200, Denmark | Website: https://galecto.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

4.509M

52 Wk Range

$2.01 - $16.07

Previous Close

$3.41

Open

$3.36

Volume

4,228

Day Range

$3.28 - $3.65

Enterprise Value

-5.997M

Cash

11.94M

Avg Qtr Burn

-3.782M

Insider Ownership

3.59%

Institutional Own.

13.03%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
GB1211 (oral galectin-3 inhibitor) + pembrolizumab (Keytruda®) Details
Cancer, Head and neck squamous cell carcinoma, Melanoma

Phase 2

Data readout

GB1211 (oral galectin-3 inhibitor) Details
Cirrhosis, Non-alcoholic steatohepatitis

Phase 2

Update

GB1211 (oral galectin-3 inhibitor) + TECENTRIQ Details
Non-small cell lung carcinoma, Cancer, Fibrosis

Phase 2a

Update

GB3226 (formerly BRM-1420) Details
Acute myeloid leukemia, Blood cancer, Cancer

IND

Submission

Failed

Discontinued

GB0139 (inhaled galectin-3 inhibitor) Details
Fibrosis, Pulmonary fibrosis, Lung disease, Idiopathic pulmonary fibrosis

Failed

Discontinued